Brought to you by:
First post-FDA approval implant of Duo venous stent system announced
Royal Philips today announced the first implant of the Duo venous stent system, indicated to treat symptomatic venous outflow obstruction in patients with chronic venous insufficiency (CVI), following premarket approval (PMA) from the Food and Drug Association (FDA). On June…
AVS receives IDE approval from FDA for pivotal intravascular lithotripsy study
Amplitude Vascular Systems (AVS) announced today that it has received an investigational device exemption (IDE) from the Food and Drug Administration (FDA) to begin its pivotal trial for pulsatile intravascular lithotripsy (IVL) therapy. The POWER-PAD-II clinical study will evaluate the…
VAM 2024: Changes to carotid stenting landscape in United States set to be discussed
Sean P. Lyden, MD, chairman of the Department of Vascular Surgery at Cleveland Clinic’s Heart, Vascular and Thoracic Institute in Cleveland, Ohio, will discuss the national coverage determination (NCD) changes passed by the Centers for Medicare & Medicaid Services (CMS)…
The top 10 most popular Vascular Specialist stories of May 2024
In April, the most read stories from Vascular Specialist include new data from the C-GUARDIANS pivotal investigational device exemption (IDE) trial presented at the Leipzig Interventional Course (LINC) 2024 (28–31 May, Leipzig, Germany); recently released randomised data show cyanoacrylate glue…
BEST-CLI and the BASIL trials: Motion sees audience move in favor of endovascular therapy over bypass
During the 2024 Charing Cross (CX) International Symposium in London, England (April 23–25), a Great Debate that pitted four global peripheral arterial disease (PAD) heavyweights against one another yielded an audience vote that went against the motion, “Bypass surgery is…
Shape Memory Medical announces first patient treated in the AAA-SHAPE randomised controlled pivotal trial
Shape Memory Medical recently announced that the first patient has been treated in the AAA-SHAPE pivotal trial. AAA-SHAPE (Abdominal aortic aneurysm sac healing and prevention of expansion) is a prospective, multicentre, randomised, open-label trial to determine safety and effectiveness of…
Aspirex achieves 78% two-year primary patency rate in P-MAX postmarket observational study
At the Leipzig Interventional Course (LINC) 2024 (28–31 May, Leipzig, Germany), Michael Lichtenberg (Arnsberg Vascular Clinic, Arnsberg, Germany) shared for the first time a 24-month update from the P-MAX study of the Aspirex (BD) endovascular thrombectomy system in the treatment…
The role of deep venous arterialization comes under scrutiny
“Every so often in vascular disease, disruptive technologies come along and the question really is, ‘Is this going to make a big impact on patient care?’” These were the words of CX Executive Board member Robert Hinchliffe, MBChB, clinical professor…
FastWave Medical announces successful 30-day first-in-human data on peripheral IVL technology
FastWave Medical has announced the 30-day results of its first-in-human (FIH) study using the company’s differentiated peripheral intravascular lithotripsy (IVL) technology. This was a prospective, single-arm study to assess the safety and feasibility of the FastWave IVL system in patients…
SVS approves FY 2024-2025 budget, sets priorities
The Society for Vascular Surgery (SVS) has unveiled its strategic plans for fiscal year 2024–2025. On April 2, the SVS Executive Board (EB) and Strategic Board of Directors (SBOD) approved the budget presented by SVS Treasurer Thomas Forbes, MD. The…